No signal suggesting an unfavourable benefit/ risk ratio for Zyrtec compared to other anti- histamines was ever detected in pharmacovigilance during the 22 years on the market; however the MAH would like to retain the contraindication: “ Patients with severe renal impairment at less than 10 ml/ min creatinine clearance .”